The Clinical Core will support projects and cores in areas relevant to clinical research. The three major components to the core include clinical trials, the prostate cancer clinical research information system, and advocacy activities.
Specific Aim 1 : To design, execute, accrue to, or otherwise facilitate the conduct and timely completion of clinical trials relevant to SPORE projects or Cores. UW, UBC, and OHSU clinical investigators will participate in this aspect of the core. Clinical trials specific to projects include pre- and post-radiation biopsy (Project 2), neoadjuvant IMC-A12 (Project 4), and MAXTAP (Project 5) studies. Numerous SPORE related trials, including InterSPORE trials, are in progress or in planning.
Specific Aim 2 : To continue to develop and enhance Caisis, the prostate cancer clinical research information system. Development of clinic abstraction templates, biospecimen clinical annotation protocol, quality control and assurance procedures, patient consent and specimen acquisition processes, and specimen tracking are priorities.
Specific Aim 3 : To support and engage the SPORE Advocacy Committee in the activities of the SPORE as well as in their own mission as a group. Goals of the committee include: continued interaction with local support groups, involvement of minority members on the committee and in clinical trials, invitation of UBC and OHSU patients to join Advocacy Committee. In order to better understand and interact with the SPORE projects, each Advocate will focus on a single project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-08
Application #
7902187
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2009-09-01
Project End
2012-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
8
Fiscal Year
2009
Total Cost
$169,983
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53

Showing the most recent 10 out of 400 publications